Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting.
Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.
Website: https://www.exscientia.ai/
Business Sector: Biotechnology
HQ Location: Oxford
Office Locations: Dundee , Osaka, Miami, Vienna, Cambridge and Boston
Number of Employees: 200
CEO: Andrew Hopkins
CTO: Garry Pairaudeau
Female Leadership:
Iva Navratilova: VP Biophysics
Amanda Galgay: VP Communications
Nazira Amra: VP Strategic Initiatives
Charlotte Deane: Chief Scientist Biologics AI
Cara Burnett: Executive Director, Talent Acquisition
Eileen Jennings-Brown - Chief Information Officer
Exscientia embraces equal opportunity and is committed to providing a diverse and inclusive community where everybody feels welcome. We welcome applications from all people regardless of background.